I think the entire industry and specifically our organizations have shown that we are in this fight with the entire system. The idea here is not necessarily to make money, per se, on the vaccine; it is to continue to invest in the development of our vaccines, as they, to your point, need to evolve. As variants come, it requires investment and an R and D perspective to actually be able to continue to evolve the vaccine to be effective.
I think there is a balance between how we continue to vaccinate the world and continue to make sure that we have medicine and good science that is evolving not only to treat the variant, but also to have, at some point, hopefully, an easier mechanism of delivery that is able to transport across the globe in a more efficient manner.